Berney T, Bühler L, Caulfield A, Oberholzer J, Toso C, Alejandro R, Cooper D K, Ricordi C, Morel P
Department of Surgery, University Hospital of Geneva, 24 Rue Micheli-Du-Crest, CH 1211 Geneva 14, Switzerland.
Swiss Med Wkly. 2001 Dec 22;131(47-48):671-80. doi: 10.4414/smw.2001.09738.
The clinical results recently reported by the Edmonton group in recipients of allogeneic islet grafts, all of whom achieved at least temporary insulin independence, has rekindled interest in transplantation of islets of Langerhans as a means to cure diabetes. Long-term islet graft survival has been achieved in a non-human primate pre-clinical model with a protocol of T-cell signaling blockade using a new monoclonal antibody. Islet xenotransplantation (namely the use of animal islets, with the aim of transplanting them into humans), or stem cell technology (the controlled differentiation of stem cells to obtain specialised cells for the treatment of diabetes) are other procedures currently being evaluated in animal models. The recent clinical success suggests that, in the near future, diabetes might be treated by islet transplantation early in the clinical course of the disease before the development of complications, and without the risks associated with conventional immunosuppression.
埃德蒙顿研究小组最近报告的同种异体胰岛移植受者的临床结果显示，所有受者均至少实现了短期胰岛素非依赖，这重新燃起了人们对移植朗格汉斯胰岛作为治疗糖尿病手段的兴趣。在一个非人类灵长类动物临床前模型中，通过使用一种新型单克隆抗体阻断T细胞信号传导的方案，实现了胰岛移植的长期存活。胰岛异种移植（即将动物胰岛移植到人类体内）或干细胞技术（通过干细胞的定向分化获得用于治疗糖尿病的特定细胞）是目前正在动物模型中评估的其他方法。最近的临床成功表明，在不久的将来，糖尿病可能在疾病临床过程早期、在并发症出现之前，通过胰岛移植进行治疗，且无需承担传统免疫抑制带来的风险。
